Mawson Infrastructure (MIGI) 10-K 25 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 23, 2015	Jun. 30, 2014
Document and Entity Information
Entity Registrant Name	OphthaliX, Inc.
Entity Central Index Key	1218683
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		10,441,251
Entity Public Float			$3,170,123

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS:
Cash and cash equivalents	$9		$422
Investment in Parent company (Note 3)	794		1,175
Prepaid expenses	209		20
Total current assets	1,012		1,617
PROPERTY AND EQUIPMENT, NET	1		1
Total assets	1,013		1,618
CURRENT LIABILITIES:
Parent company (Note 9)	2,457		1,487
Other accounts payable and accrued expenses	246		263
Total current liabilities	2,703		1,750
NON-CURRENT LIABILITIES:
Derivative related to Service Agreement (Note 4)		[1]	7
Share capital
Preferred Stock - Authorized : 1,000,000 shares at December 31, 2014 and 2013, Issued and Outstanding: 0 shares at December 31, 2014 and 2013
Common Stock of $0.001 par value - Authorized: 100,000,000 shares at December 31, 2014 and 2013, Issued and Outstanding: 10,441,251 shares at December 31, 2014 and 2013	10		10
Additional paid-in capital	5,494		5,469
Accumulated other comprehensive income	102		483
Accumulated deficit	-7,296		-6,101
Total stockholders' deficiency	-1,690		-139
Total liabilities and stockholders' deficiency	$1,013		$1,618
[1]	Represent amount lower than $1

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred Stock, shares authorized	1,000,000	1,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common stock shares issued	10,441,251	10,441,251
Common Stock, shares outstanding	10,441,251	10,441,251

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
Research and development	$721	$1,759
General and administrative	425	1,511
Total operating expenses	1,146	3,270
Financial expenses (income) , net (Note 8)	49	-433
Net loss	1,195	2,837
Net loss per share:
Basic and Diluted loss per share	$0.11	$0.27
Weighted average number of shares of Common Stock used in computing basic and diluted net loss per share	10,441,251	10,441,251
Available-for-sale investments:
Changes in net unrealized loss (income)	381	-523
Less: reclassification adjustment for net loss included in net loss		40
Total other comprehensive loss (income)	381	-483
Comprehensive loss	$1,576	$2,354

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (USD $)	Total	Shares of Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive income
In Thousands, except Share data
Beginning Balance at Dec. 31, 2012	$1,617	$10	$4,871	($3,264)
Beginning Balance, Shares at Dec. 31, 2012		10,441,251
Stock based compensation	598		598
Unrealized gain from investment in Parent company	483				483
Net loss	2,837			-2,837
Ending Balance at Dec. 31, 2013	-139	10	5,469	-6,101	483
Ending Balance, Shares at Dec. 31, 2013		10,441,251
Stock based compensation	25		25
Unrealized gain from investment in Parent company	-381				-381
Net loss	1,195			-1,195
Ending Balance at Dec. 31, 2014	($1,690)	$10	$5,494	($7,296)	$102
Ending Balance, Shares at Dec. 31, 2014		10,441,251

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Cash flows from operating activities:
Net loss	$1,195		$2,837
Adjustments to reconcile net loss to net cash used in operating activities:
Decrease (increase) in prepaid expenses	-189		238
Increase (decrease) in other account payables and accrued expenses	-17		64
Increase in Parent company balance	970		1,559
Change in fair value of the derivative related to Service Agreement	-7		-463
Loss from sale of investments in Parent company			26
Stock based compensation	25		598
Depreciation		[1]	1
Net cash used in operating activities	-413		-814
Cash flows from investing activities:
Proceed from sale of Parent company shares, net			511
Purchase of property and equipment			-2
Net cash provided by investing activities			509
Cash flows from financing activities:
Net cash provided by financing activities
Change in cash and cash equivalents	-413		-305
Cash and cash equivalents at the beginning of the year	422		727
Cash and cash equivalents at the end of the year	$9		$422
[1]	Represent amount lower than $1

General

General	12 Months Ended
	Dec. 31, 2014
General [Abstract]
GENERAL	NOTE 1:-	GENERAL
		a.	OphthaliX Inc. (the "Company" or "OphthaliX"), originally incorporated in the State of Nevada on December 10, 1999 under the name Bridge Capital.com Inc., was a nominally capitalized corporation that did not commence its operations until it changed its name to Denali Concrete Management Inc. in March 2001. Denali was a concrete placement company specializing in providing concrete improvements in the road construction industry. Denali operated primarily in Anchorage, Alaska, placing curb and gutter, sidewalks and retaining walls for state, municipal and military projects.
	In December 2005, the Company ceased its principal business operations and focused its efforts on seeking a business opportunity, becoming a public shell company in the U.S.
	Eye-Fite Ltd. ("Eye-Fite" or the "Subsidiary") was founded on June 27, 2011 in contemplation of the execution of a transaction between Can-Fite BioPharma Ltd. (the "Parent company" or "Can-Fite"), a public company in Israel and U.S, and the Company, as further detailed in Note 1b below.
	The Company and its Subsidiary conduct research and development activities using an exclusive worldwide license for CF101, a synthetic A3 adenosine receptor, or A3AR, agonist (known generically as IB-MECA) solely for the field of ophthalmic diseases after the consummation of the transaction. See also Note 1b2.
	Following the transaction, Denali changed its name to OphthaliX Inc. and also changed its corporate domicile from Nevada to Delaware.
		b.	Reverse Recapitalization and related arrangements:
		1	Recapitalization:
	On November 21, 2011 (the "Closing Date"), Can-Fite purchased 8,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) in exchange for all of the issued and outstanding ordinary shares of Eyefite pursuant to the terms of a stock purchase agreement (the “Purchase Agreement”).  As a result, Eyefite became a wholly-owned subsidiary of the Company and Can-Fite became its majority stockholder and a parent.
	Also on November 21, 2011, the Company issued a warrant to Can-Fite by which Can-Fite has the right, until the earlier of (a) the November 21, 2016 and (b) the closing of the acquisition of the Company by another entity, resulting in the exchange of the Company’s outstanding common shares such that its stockholders prior to such transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity, to convert its right to the Additional Payment (as defined below) into 480,022 shares of Common Stock (subject to adjustment in certain circumstances).  The per share exercise price for the shares is $5.148.  This warrant may be exercised on either a cash or a cashless basis, provided that if the warrant is exercised on a cashless basis, the warrant must be exercised in whole, not in part.
	Simultaneously with the transactions described above, the Company completed a private placement of shares of Common Stock for gross proceeds of $3,330 through the sale of 646,776 shares to third party investors and sold 466,139 shares of Common Stock to Can-Fite in exchange for 714,922 ordinary shares of Can-Fite (representing approximately 7% of Can-Fite's issued and outstanding share capital as of the Closing Date), valued at $2,400 (as determined by reference to the previous trading day’s closing price for Can-Fite shares on the Tel Aviv Stock Exchange), and 97,112 shares to Can-Fite for gross proceeds of $500 (collectively, together with the shares issued to the investors, the “Financing”).  In addition, the Company issued to Can-Fite and each of the other investors, for each four shares of the Company’s Common Stock purchased in the Financing, nine warrants valid for a period of five years from the closing of the Financing to acquire two shares of the Company for an exercise price of $7.74. The warrants do not contain nonstandard anti-dilution provisions (see also Note 6b).
	In accordance with the Israeli Securities Law (1968), Section 15C and related Securities Regulations, the ordinary shares issued by Can-Fite to OphthaliX have a "Resale Restriction Period", which consists of one year of full restriction and a liquidation period of eight consecutive quarters. As such, OphthaliX was eligible to sell 12.5% of the Can-Fite ordinary shares it holds every quarter since November 21, 2012. As of December 31, 2014, no restrictions remained on selling the abovementioned shares under the Israeli Securities Law (1968), Section 15C and related Securities Regulations.
	On June 17, 2013, the Company sold 268,095 Can-Fite ordinary shares for a total consideration of $511. As of December 31, 2014, the Company held 446,827 Can-Fite ordinary shares, representing approximately 2.05% of Can-Fite's issued and outstanding share capital.
	The transaction was accounted for as a reverse recapitalization which is outside the scope ASC 805, Business Combinations. Under reverse capitalization accounting, EyeFite is considered the acquirer for accounting and financial reporting purposes, and acquired the assets and assumed the liabilities of the Company. Assets acquired and liabilities assumed are reported at their historical amounts. Consequently, the condensed consolidated financial statements of the Company reflect the operations of the acquirer for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former shareholders of the legal acquirer and a recapitalization of the equity of the accounting acquirer. These condensed consolidated financial statements include the accounts of the Company since the effective date of the reverse capitalization and the accounts of EyeFite since inception. Following the consummation of all of the transactions contemplated by the Purchase Agreement, the Financing, and other agreements entered into on the Closing Date, Can-Fite became the beneficial holder of 82% of the Company’s Common Stock.
		2	License and research and development services from Can-Fite:
	In connection with the consummation of the recapitalization transaction, the Company and Can-Fite entered into a license agreement, pursuant to which Can-Fite granted EyeFite a sole and exclusive worldwide license for the use of CF101, solely in the field of ophthalmic diseases. EyeFite will be obligated to make to the U.S. National Institutes of Health ("NIH"), with regard to the patents of which are included in the license to EyeFite, for as long as the license agreement between the Company and NIH remains in effect, a nonrefundable minimum annual royalty fee and potential future royalties of 4.0% to 5.5% on net sales.
	In addition, the Company will be obligated to make certain milestone payments ranging from $25 to $500 upon the achievement of various development milestones for each indication. During 2013, the Company accrued an amount of $75 related the Glaucoma phase II clinical trial. EyeFite will also be required to make payments of 20% of sublicensing revenues, excluding royalties and net of the required milestone payments. During 2014, the Company did not reach any milestone or generate revenue that would trigger additional payments to Can-Fite.
	As of December 31, 2014 the aggregate amount accrued for these milestones payment is $175.
	In addition, following the closing of the recapitalization transaction, Can-Fite, OphthaliX and EyeFite entered into a service agreement (the "Service Agreement"). Pursuant to the terms of the Service Agreement, Can-Fite will manage the research and development activities relating to pre-clinical and clinical studies for the development of the ophthalmic indications of CF101. In consideration for Can-Fite's services, EyeFite will pay to Can-Fite a service fee (consisting of all expenses and costs incurred by Can-Fite plus 15%). In addition, the Company is committed to future additional payments equal to 2.5% of any and all proceeds received by EyeFite relating to the activities regarding the drug (the "Additional Payment").
	According to the Service Agreement, Can-Fite will have the right, at any time until November 21, 2016, to convert the Additional Payment into an additional 480,022 shares of Common Stock of the Company for total consideration of $2,471 (subject to adjustment in certain circumstances - See also Note 6).
		c.	The Company devotes most of its efforts toward research and development activities. As of December 31, 2014, the Company does not have sufficient capital resources to conduct its research and development activities until commercialization of the underlying products.
	The Company is addressing its liquidity issues by implementing initiatives to raise additional funds as well as other measures that will allow it to cover its anticipated budget deficit. Such initiatives include a plan to monetize part or all of the Company's investment in Can-Fite's ordinary shares. In addition, in February 2013, which has been updated periodically (most recently in March 2015), Can-Fite issued to the Company a formal letter stating that Can-Fite agrees to defer payments owing to it under the Services Agreement from January 31, 2013 for the performance of the clinical trials of CF101 in ophthalmic indications until the completion of fundraising by the Company sufficient to cover such deferred payments. In addition, in March 2015, Can-Fite issued a financial support letter pursuant to which it committed to cover any shortfall in the costs and expenses of operations of the Company which are in excess of the Company's available cash to finance its operations, including cash generated from any future sale of Can-Fite shares held by the Company. Both letters remain in effect for a period of at least 14 months from March 2015 and any related balance bears interest at a rate of 3% per annum.
	The Company's inability to raise funds to conduct its research and development activities will have a severe negative impact on its ability to remain a viable company. Liquidity resources, as of December 31, 2014, together with the Parent company support letters described above, will be sufficient maintain of the Company's operations for at least for twelve months.
	As of December 31, 2014, the deferred payments to Can-Fite totaled $2,457. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities. If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of all of its products or may be required to delay part of the development programs.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:-	SIGNIFICANT ACCOUNTING POLICIES
	The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").
		a.	Use of estimates:
	The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
		b.	Financial statements in U.S. dollars:
	The accompanying financial statements have been prepared in U.S. dollars, the functional and reporting currency of the Company.
	Although the majority of the Company and its Subsidiary's operations are conducted in Israel, most of their expenses are in U.S dollar. Therefore, the Company's management believes that the U.S dollars is the functional currency of the primary economic environment in which the Company and its Subsidiary operate.
	Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars in accordance with ASC 830-10, "Foreign Currency Matters". All transactions gains and losses of the re-measurement of monetary balance sheets items are reflected in the consolidated statements of comprehensive loss as financial income or expenses, as appropriate.
		c.	Principles of consolidation:
	The consolidated financial statements include the accounts of the Company and its Subsidiary. Intercompany transactions and balances have been eliminated upon consolidation.
		d.	Cash equivalents:
	Cash equivalents include short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less from time of deposit.
		e.	Prepaid expenses:
	All prepaid expenses are composed of clinical trials drug-kits which expense based on a percentage of completion method of the related clinical trials.
		f.	Investment in Parent company:
	In accordance with ASC320, the accounting for the Company's investment in the equity securities depend on the remaining period of the tradability restriction in its respective market of the shares (as described in Note 1b).
	Shares that are restricted for less than one year re-measured to reflect fair value at each cutoff date. These securities are classified as available-for-sale securities carried at fair value, with unrealized gains and losses reported as a separate component of stockholders' equity under accumulated other comprehensive income in the consolidated balance sheets. Realized gains and losses on sales of available-for-sale securities are included as financials income, net in the consolidated statements of comprehensive loss. As of December 31, 2014, there are no restrictions on selling such shares.
	The Company recognizes an impairment charge when a decline in the fair value of its investments in securities is below the cost basis of such securities is judged to be other than temporary. Factors considered in making such a determination include the duration and severity of the impairment, the reason for the decline in value, the potential recovery period and the Company's intent to sell, including whether it is more likely than not that the Company will be required to sell the investment before recovery of cost basis. For securities that are deemed other-than-temporarily impaired, the amount of impairment recognized as part of financial income, net, net in the statement of comprehensive loss and is limited to the amount related to credit losses, while impairment related to other factors recognized in other comprehensive loss. As of December 2014 and 2013 no impairment was recognized.
		g.	Property and equipment, net:
			Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets at the following annual rates:
				%
		Computer equipment			33
		h.	Impairment of long-lived assets:
	The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360, "Property, Plant and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. As of December 31, 2014 and 2013, no impairment losses have been identified.
		i.	Research and development expenses:
	All research and development costs are charge to expense as incurred.
		j.	Accounting for stock-based compensation:
	The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation" ("ASC 718"). ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company's consolidated statements of comprehensive loss.
	The Company recognizes compensation expenses for the value of its awards granted based on the accelerated recognition method over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	The Company estimates the fair value of stock options granted using the binomial option pricing-model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the early exercise multiply. Expected volatility was calculated based upon historical volatilities of similar entities in the related sector index. The early exercise multiply is representing the value of the underlying stock as a multiple of the exercise price of the option which, if achieved, results in exercise of the option. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
	The Company applies ASC 505-50, "Equity-Based Payments to Non-Employees" with respect to options and warrants issued to non-employees.
		k.	Basic and diluted net loss per share:
	Basic net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each period. Diluted net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each period, plus dilutive potential Common Stock considered outstanding during the period, in accordance with ASC topic 260, "Earnings Per Share" ("ASC 260").
	The total weighted average number of shares related to the outstanding warrants and options excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,453,638 and 1,437,315 for the years ended December 31, 2014 and 2013, respectively.
		l.	Income taxes:
	The Company and its Subsidiary account for income taxes and uncertain tax positions in accordance with ASC 740, "Income Taxes" ("ASC 740"). ASC 740 prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company and its subsidiary provide a full valuation allowance, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized.
	The Company implements a two-step approach to recognize and to measure uncertain tax positions in accordance with ASC 740. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2014 and 2013, no liability for unrecognized tax benefits was recorded as a result of the implementation of ASC 740.
		m.	Concentrations of credit risk:
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, investment in Parent company and prepaid expenses.
	Cash and cash equivalents are deposited with a major bank in Israel. The Company's management believes that the financial institution that holds the Company's investments is an institution with high credit standing, and accordingly, minimal credit risk exists with respect to these investments.
		n.	Fair value of financial instruments:
	The carrying amounts of the Company's financial instruments, including cash and cash equivalents, investment in Parent company, prepaid expenses, accounts receivable, other accounts payable and accrued expenses, approximate fair value because of their generally short-term maturities.
	The Company adopted ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"). ASC 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to release a liability in an orderly transaction between market participants.
	As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
		Level 1 - Observable input that reflects quoted prices (unadjusted) for identical assets or liabilities in active markets.
		Level 2 - Include other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and credit ratings.
		Level 3 - Unobservable inputs which are supported by little or no market activity.
	The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
		o.	Impact of recently issued Accounting Standards:
	In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. Although the Company has elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the Jumpstart Our Business Act of 2012, since early adoption is permitted the Company chose to early adopt the update effective June 30, 2014 consolidated financial statement.
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity s Ability to Continue as a Going Concern, which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements.

Investment_in_Parent_Company

Investment in Parent Company	12 Months Ended
	Dec. 31, 2014
Investment in Parent Company [Abstract]
INVESTMENT IN PARENT COMPANY	NOTE 3: -	INVESTMENT IN PARENT COMPANY
	The Company reviews various factors in determining whether it should recognize an other-than-temporary impairment charge for its marketable securities, including its intent and ability to hold the investment for a period of time sufficient for any anticipated recovery in market value, the length of time and extent to which the fair value has been less than its cost basis. No such other-than-temporary-impairment was identified during 2014 and 2013.
	On June 17, 2013, the Company sold 268,095 Can-Fite's ordinary shares for a total consideration of $511. As a result of such sale the Company recorded loss in the amount of $26 as part of financial income, net in the Consolidated Statements of Comprehensive Loss.
	As of December 31, 2013, the investment in Parent company's shares disclosed with discount to reflect the resale restriction (see also note 1.b.1). In measuring the fair value, the Company used an average of Protective Put Option with Asian Put option models. In estimating the fair value, the Company used Black-Scholes option-pricing model with the following weighted-average assumptions as of December 31, 2013: risk-free interest rates ranging from 0.89% to 0.93%; dividend yields of 0%; volatility factors of 77.4%; and a weighted-average contractual life of the options of between 0.14 and 0.64 years.
	As of December 31, 2014, the Company holds 446,827 of Can-Fite's outstanding ordinary shares. The Company's investment in Parent company is $794 (according to its quoted market price in the Tel-Aviv Stock Exchange) and classified as short term assets. During 2014, the related unrealized losses derive from the change in the investment totaled $381.

Derivative_Related_to_Service_

Derivative Related to Service Agreement	12 Months Ended
	Dec. 31, 2014
Derivative Related to Service Agreement [Abstract]
DERIVATIVE RELATED TO SERVICE AGREEMENT	NOTE 4:-	DERIVATIVE RELATED TO SERVICE AGREEMENT
	In contemplation with the Reverse Recapitalization described in Note 1b, on November 21, 2011 the Company entered into the Service Agreement.
	According to the Service Agreement, in consideration for Can-Fite's services, Eye-Fite shall pay to Can-Fite a service fee (consisting of all expenses and costs incurred by Can-Fite plus 15%). Furthermore, the Company is required to pay Can-Fite an additional payment of 2.5% from all future proceeds received by OphthaliX or any of its affiliates in relation to CF101. Can-Fite has the right (the "Exchange Right" or the "Derivative"), at any time from November 21, 2011 until November 21, 2016, to convert its right for the additional payment into a warrant (the "Warrant") to purchase 480,022 shares of Common Stock of the Company. The exercise price for all the shares shall be an aggregate of US $2.5 million, equal to a per share exercise price of $5.148.
	The Company's management applied ASC 815 to evaluate whether the Exchange Right (contingent call option to holders) instrument is a financial instrument that has the characteristics of a derivative. In specific the Company's management had also evaluated ASC 815-10-15-74(a) scope exception.
	The Company's management concluded that the Exchange Right doesn't have fixed settlement provisions, and therefore, should be classified as liability at inception. The Exchange Right is being re-measured at fair value each reporting period until date of exercise or expiration with the change in value reported in the statements of comprehensive loss (as part of financial income, net).
	Consequently, the Company recorded as part of the Reverse Recapitalization a liability related to the Exchange Right in the amount of $438 based on its fair value. Issuance expenses that were allocated to this component, amounted to $50, were expensed immediately and were included as part of financial expenses in the consolidated statements of comprehensive loss for the period ended in December 31, 2011 (see Note 5 for the re-measurement at year end).
	The fair value of the Derivative as of December 31, 2014 and 2013 amounted to $0 and $7, respectively and was determined using the binomial option-pricing model. The aforementioned option-pricing model requires a number of assumptions, of which most significant are the expected stock price volatility and the expected term.
	In estimating the derivative fair value, the Company used the following assumptions:
				31-Dec
				2014			2013
		Risk-free interest rate (1)			0.54	%		0.78	%
		Expected volatility (2)			57.51	%		58.41	%
		Expected life (in years) (3)			1.92			2.92
		Expected dividend yield (4)			0			0
		-1	Risk-free interest rate - based on the yields from U.S. treasury bonds with different periods to maturity (according to different projection periods).
		-2	Expected volatility - was calculated based on actual historical stock price movements of the Parent Company over a term that is equivalent to the expected term of the option.
		-3	Expected life - the expected life of the conversion feature was based on the term of the derivative.
		-4	Expected dividend yield - was based on the fact that the Company has not paid dividends to its stockholders in the past and does not expect to pay dividends to stockholders in the foreseeable future.
	The Company considers an active market to be one in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis, and views an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Since the quoted market value of the Company's Common Stock was based on a sporadically traded stock with little or no volume, the Company's management determined the Company's stock price fair value based on ASC 820 Fair Value Measurement using the income approach assisted by a third party specialist. Consequently, the Company used the estimates stock price fair value in the underlying assumptions of the computation of the fair value of the derivative related to the Service Agreement.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 5:-	FAIR VALUE MEASUREMENTS
	In accordance with ASC 820, the Company measures its marketable securities and embedded derivatives at fair value. Marketable securities fair value is based on quoted prices for identical assets in active markets and other inputs (such as risk free interest and volatility) that are directly or indirectly observable in the marketplace. The assets are classified within Level 1 and Level 2 on the fair value hierarchy. Derivatives are classified within Level 3 because they are valued using valuation techniques. Some of the inputs to these models are unobservable in the market and are significant.
	The following table provides information by value level for financial assets and liabilities that are measured at fair value, as defined by ASC 820, on a recurring basis as of December 31, 2014 and 2013.
				31-Dec-14
				Fair value measurements
		Description		Fair Value			Level 1(1)		Level 2(2)		Level 3(3)
		Investment in Parent company		$	794		$	794	$	-	$	-
		Derivative related to Service Agreement			*	)		-		-		*	)
		Total Financial Assets, net		$	794		$	794	$	-	$	-
	*) Represent amount lower than $1
				31-Dec-13
				Fair value measurements
		Description		Fair Value			Level 1(1)		Level 2(2)		Level 3(3)
		Investment in Parent company		$	1,175		$	514	$	661	$	-
		Derivative related to Service Agreement			(7	)		-		-		(7	)
		Total Financial Assets, net		$	1,168		$	514	$	661	$	(7	)
		-1	Represents the portion of the Parent company's shares that has no trading restrictions.
		-2	Represents the portion of the Parent company's shares that has trading restrictions.
		-3	Fair value measurements using significant unobservable inputs (Level 3).
	The following table presents the changes in Level 3 instruments measured on a recurring basis for the year ended December 31, 2014 and 2013. The Company's Level 3 instruments consist of Derivative (see Note 4).
		Balance at January 1, 2013		$	470
		Change in fair value of derivatives			(463	)
		Balance at December 31, 2013			7
		Change in fair value of derivatives			(7	)
		Balance at December 31, 2014			*	)
	*) Represent amount lower than $1

Share_Capital

Share Capital

12 Months Ended

Dec. 31, 2014

Share Capital [Abstract]

SHARE CAPITAL

NOTE 6:-

SHARE CAPITAL

a.

Shares of Common Stock:

The shares of Common Stock represent the legal acquirer, meaning OphthaliX's share capital as of the transaction date.

Shares of Common Stock confer upon the holders the right to receive notice to participate and vote in the general meetings of the Company and the right to receive dividends, if declared.

On July 18, 2013 the Company's stockholders approved a reverse stock split of one share for each four and one-half shares outstanding (1:4.5) (the "Reverse Split"). The Reverse Split became effective as of the close of business on August 6, 2013.

All shares of Common Stock, warrants, options, per share data and exercise prices included in these financial statements and notes for all periods presented have been retroactively adjusted to reflect the Reverse Split with respect to the Company's shares of Common Stock.

b.

Warrants:

In contemplation with the Reverse Recapitalization, it was agreed that for each four shares of Common Stock purchased by the New Investors and Can-Fite, they will be granted by the Company nine warrants to acquire two share of Common Stock of the Company. The exercise price of the warrants is $7.74 per share of Common Stock. The warrants are exercisable for a period of five years from their date of grant. The warrants do not contain nonstandard anti-dilution provisions.

According to ASC 815-40-15 and 25 instructions, the Company's management evaluated whether the warrants are entitled to the scope exception in ASC 815-10-15-74 (as the warrants meet the definition of a derivative under ASC 815-10-15-83). Based on their straight forward terms (i.e., fix exercise price, no down-round or other provisions that will preclude them from being considered indexed to the Company's own stock), the Company's management concluded that the warrants should be classified as equity at inception.

In contemplation of the transaction, the Company issued a total of 532,870 warrants to acquire an aggregate of 118,415 shares of Common Stock to consultants and brokers involved in the transaction with a fair value in total of $329 (the "Adviser Warrants").

Therefore, the fair value of the Adviser Warrants was accounted as issuance expenses, whereas $304 allocated to equity component and were deducted from additional paid in capital, $25 were allocated to a derivative component and expensed immediately as part of financial expenses. All the Adviser Warrants are fully vested. The Company estimates the fair value of Adviser Warrants granted using the Black-Scholes option-pricing model with the following weighted-average assumptions: risk-free interest rates of 0.92%, dividend yield of 0%, volatility factors of the expected market price of the Parent company's ordinary shares of 76.23% and expected life of the options of 3.72 years. The Adviser Warrants are exercisable upon the payment of $5.148 per share of Common Stock. As of December 31, 2014 and 2013 the intrinsic value of the Adviser Warrants is zeroed.

On November 12, 2012, the Company, complying with the undertaking taken as part of the recapitalization of the Company on November 21, 2011, issued to certain investors and Can-Fite1,455,228 and 1,267,315 warrants to acquire 323,384 and 281,625 shares of Common Stock of the Company, respectively . The exercise price of such warrants is $7.74 per share. The warrants are exercisable for a period of five years from their date of grant and do not contain any non- standard anti-dilution provisions.

c.

Stock option plan and grant:

On January 2, 2012, the Board of Directors approved the adoption of the 2012 Stock Incentive Plan (the "2012 Plan"). The 2012 Plan was approved by the Company's stockholders and became effective on February 6, 2012. Under the 2012 Plan, the Company may grant its officers, directors, employees and consultants, stock options, restricted stock and restricted stock units ("RSUs") of the Company. Each stock option granted shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will be granted with a term in excess of 10 years.

Upon the adoption of the 2012 Stock Option Plan the Company reserved for issuance 1,088,888 shares of Common Stock. As of December 31, 2014 the Company has 971,388 shares of Common Stock available for future grant under the 2012 Plan.

On January 2013, the Board of Directors approved the adoption of an annex to the 2012 Plan. This Annex only applies to the Israeli grantees in order to comply with the requirements set by Israeli law in general and in particular with the provisions of section 102 of the Israeli tax ordinance.

1

In January 2012, the Company granted to one of its board members, options to purchase 52,222 shares of Common Stock of the Company at an exercise price of $9.00 per share. The options shall be vested in a period of 36 months so long as he remains a director until fully vested. The options were granted under the Company's 2012 Plan and shall expire 10 years from the grant date. The agreement prohibits the board member from employment or connection with, or holding any office in, any business or undertaking which competes with any business of the Company or is a customer or supplier of the Company.

2

On December 12, 2012, the Board of Directors of the Company approved the appointment of a Chief Executive Officer ("Former CEO") of the Company effective January 1, 2013. The Board of Directors also approved an employment agreement of the Former CEO, which became effective on January 1, 2013. The agreement was terminated on February 25, 2013.

In contemplation of the termination of the Former CEO, the Board of Directors approved a grant of options to the Former CEO. He received options to acquire 8,701 shares of Common Stock at an exercise price of $5.29 in accordance with the terms of the 2012 Plan and the Israeli Annex to the Company's 2012 Plan and which options expired on August 28, 2013.

3

On February 28, 2013, the Board of Directors approved the appointment of a Chief Executive Officer (the "Second Former CEO") of the Company, effective March 1, 2013. The Board of Directors also approved an amendment, dated February 28, 2013, to the existing employment agreement and non-competition agreement, dated February 22, 2011, between Can-Fite and the Second Former CEO whereby the Second Former CEO agreed to serve as Chief Executive Officer of OphthaliX while at the same time continuing to serve as Vice-President of Business Development of Can-Fite. He was to devote approximately 50% of his time to each position and the Company agreed to pay one-half of the compensation owed to him under the February 22, 2011 Employment Agreement with Can-Fite.

On April 22, 2013, the Company's Board of Directors approved the grant of options to the Second Former CEO. In accordance with the option agreement, he received options to acquire 104,412 shares of Common Stock at an exercise price of $5.29 (the "Time Based Options") which were to expire ten years from the grant date. The Time Based Options were to vest over a period of three years on a quarterly basis over twelve consecutive quarters from the date of commencement of the employment. In addition, the Company's Board of Directors also approved the grant of an aggregate of 469,855 options to acquire 104,412 shares of Common Stock of OphthaliX at an exercise price of $5.29 in accordance with the terms of the 2012 Plan, and which were to expire ten years from the grant date. These options were to vest upon the achievement of certain business and financial milestones, as defined in the agreement governing the same.

On June 2, 2014 by mutual agreement with the Company's Second Former CEO, his employment agreement was terminated effective July 28, 2014. All options to acquire the Company's stocks of common shares which were not vested prior to the effective date were forfeited. All of the vested options were exercisable 90 days from the effective date and none were exercised.

According to ASC 718 compensation cost initially is recognized based on an estimate of instruments expected to vest. Each reporting period a company must reevaluate its estimate of the number of instruments that ultimately will be forfeited if the requisite service has not been or is not expected to be provided. The effect of this change in estimated forfeitures is accounted for as a cumulative effect of a change in an accounting estimate in the period that the estimate is revised.

Based on the above accounting policy, for the year ended December 31, 2014 the Company reversed all previous compensation which related to the unvested option at amount of $85.

4

On May 9, 2013, the Company's Board of Directors granted options, which were modified on May 29, 2013 as to number and exercise price, to purchase 13,055 shares of Common Stock to the Company's Chief Financial Officer.  These options have an exercise price of $9.00 per share and expire on May 29, 2023.  29,375 of these options vested immediately and the remaining 29,375 will vest over a period of three years on a quarterly basis for 12 consecutive quarters from the date of the grant. The Company accounted for the modification in accordance with ASC-718 "Compensation – Stock Compensation", which measures the fair value of the replacement award against the fair value of the cancelled award on the cancellation date. During 2013 the Company recognized a total compensation of $62 which $38 of them related to the modification.

5

On May 9, 2013 the Company's Board of Directors approved the grant of options, with the same terms as the options granted to the Company's Chief Financial Officer as described above, to certain members of the Company's Board of Directors, its Secretary and a director of EyeFite. The option grants to the Company's Secretary and the EyeFite director were rescinded by the Company's Board of Directors on June 13, 2013 and the respective grantees waived any rights in and to such options.  The Company accounted for these option awards as a cancellation of awards and, in accordance with ASC-718 "Compensation – Stock Compensation", all unrecognized compensation costs were recorded on the cancellation date amounted to $211. The options to be granted to the members of the Company's Board of Directors, which also required the approval of the Company's stockholders, were never granted due to the failure to obtain such stockholder approval.

6

On July 1, 2013, the Board of Directors approved the appointment of a new director. As part of the agreement with the director, the Company granted him ten-year options under the 2012 Plan to purchase 52,222 shares of Common Stock of the Company at $6.638 per share. The options vest in 12 equal installments on the last day of each fiscal quarter commencing on September 30, 2013, so long as he remains a director.

The following table presents the assumptions used to estimate the fair values of the stock options granted in the period presented:

Year ended

December 31,

Description

2014

2013

Risk-free interest rate

-

1.72%-2.5%

Expected volatility

-

68.5%-71.6%

Dividend yield

-

0

Contractual life

-

10

Early Exercise Multiple (Suboptimal Factor)

-

3

Fair value of options granted during the period

-

$

0.54-0.6

During the year ended December 31, 2014 the Company did not issue any stock options.

The following table summarizes the activity of stock options:

Shares Subject to Options Outstanding

Description

Number of

Weighted

Weighted-

Aggregate

Shares

Average

Average

Exercise

Remaining

Intrinsic

Price

Contractual

Term (in years)

Value(1) (in thousands)

Outstanding at beginning of year

326,324

6.25

9.15

$

-

Forfeited/cancelled

(208,824

)

5.29

-

-

Outstanding at the end of year

117,500

7.96

7.8

$

-

Exercisable at the end of the year

88,125

8.39

7.6

$

-

Vested and expected to be vested

117,500

7.96

7.8

$

-

-1

The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the closing price of the shares of the Company's Common Stock of $0.96 as of December 31, 2014.

Stock-based compensation expenses recognized during the years ended December 31, 2014 and 2013 totaled to $25 and $597, respectively.

As of December 31, 2014, there was $25 of unrecognized stock-based compensation expense all of which is related to stock options. This unrecognized compensation expense is expected to be recognized over a weighted-average period of approximately 0.7 years.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 7:-	INCOME TAXES
	The Company and its Israeli Subsidiary are separately taxed under the domestic tax laws of the state of incorporation of each entity.
		a.	Net operating losses carryforward:
	The Company is subject to U.S. income taxes. As of December 31, 2014, the Company had net operating loss carryforwards for federal income tax purposes of approximately $1,503 which expire in the years 2018 to 2034. The Company has no operating loss carry forwards for state income tax purposes. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the "change in ownership" provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.
	The Company's Subsidiary in Israel has estimated accumulated losses for tax purposes as of December 31, 2014, in the amount of approximately $2,523 which may be carried forward and offset against taxable income in the future for an indefinite period.
		b.	According to the law in Israel the results of the Israeli subsidiary for tax purposes are measured in nominal values.
		c.	Loss before taxes is comprised as follows:
				Year ended
				December 31,
				2014			2013
		Domestic		$	367		$	869
		Foreign (Israel)			828			1,968
				$	1,195		$	2,837
		d.	Deferred taxes:
	Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and the Subsidiary's deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and the Subsidiary’s deferred tax assets are as follows:
				December 31,
				2014			2013
		Operating loss carryforward		$	1,268		$	952
		Research and development expenses			205			229
		Investment in Parent company			282			130
		Deferred tax assets before valuation allowance			1,755			1,311
		Valuation allowance			(1,755	)		(1,311	)
		Net deferred tax asset		$	-		$	-
	The Company has provided valuation allowance in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences.
	Management currently believes that since the Company and the Subsidiary have a history of losses it is more likely than not that the deferred tax regarding the loss carryforward and other temporary differences will not be realized in the foreseeable future.
		e.	Tax rates applicable to the income of the Company:
	The Israeli corporate tax rate is 25% in 2013 and 26.5% in 2014.
	On July 30, 2013, the Israeli Parliament approved the second and third readings of the Economic Plan for 2013-2014 ("Amended Budget Law") which includes fiscal changes whose main aim is to enhance the collection of taxes in those years. These changes include, among others, raising the Israeli corporate tax rate from 25% to 26.5% effective from January 1, 2014.
	The deferred tax balances included in the financial statements as of December 31, 2014 are calculated according to the new tax rates that were substantially enacted as of the balance sheet date and therefore comply with the above changes, as applicable to the Company.
	The corporate tax in the U.S. applying to the Company (incorporated in state of Delaware), consists of a progressive corporate tax at a rate of up to 35% plus state tax and local tax at rates depending on the state and the city in which the company manages its business. In the Company's estimation, it is subject to approximately a 40% tax rate.

Finance_Expenses_Income_Net

Finance Expenses (Income), Net	12 Months Ended
	Dec. 31, 2014
Finance Expenses (Income), Net [Abstract]
FINANCE EXPENSES (INCOME), NET	NOTE 8:-	FINANCE EXPENSES (INCOME), NET
			Year ended
			December 31,
			2014			2013
		Bank fees	$	4		$	4
		Interest expenses		52			17
		Revaluation of derivative related to service agreement		(7	)		(463	)
		Loss from sale of Parent company shares		-			26
		Foreign currency translation adjustments		*	)		(17	)
		Finance expenses (income), net	$	49		$	(433	)
	*) Represent amount lower that 1$.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9:-	RELATED PARTY TRANSACTIONS
	On November 21, 2011, the Company entered into a license agreement with the Parent company, (for further information, refer to Notes 1b and 6). Details of the transactions with related parties are depicted in the following tables:
	Transactions with related parties:
				Year ended
				December 31,
				2014			2013
		Research and development expenses (1)		$	701		$	1,530
		General and administrative expenses (2)		$	115		$	152
		Finance expenses (income), net (1)		$	45		$	(446	)
	Balances with Related Parties:
				December 31,
				2014			2013
		Parent company (1)		$	(2,457	)	$	(1,487	)
		Investment in Parent company (3)		$	794		$	1,175
		Other account payables and accrued expenses (1)		$	(175	)	$	(175	)
		Derivative related to service agreement (1)		$	*	)	$	(7	)
		-1	Related to Service Agreement. (See Notes 1.b.2 and 1c).
		-2	Related to Service Agreement. (See Notes 1.b.2 and 1c) and to the CEO employment agreement.
		-3	Related to Investment in Parent company. See Notes 2.e and Note 3.
	*) Represent amount lower than $1

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Significant Accounting Policies [Abstract]
Use of estimates
		a.	Use of estimates:
	The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Financial statements in U.S. dollars
		b.	Financial statements in U.S. dollars:
	The accompanying financial statements have been prepared in U.S. dollars, the functional and reporting currency of the Company.
	Although the majority of the Company and its Subsidiary's operations are conducted in Israel, most of their expenses are in U.S dollar. Therefore, the Company's management believes that the U.S dollars is the functional currency of the primary economic environment in which the Company and its Subsidiary operate.
	Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars in accordance with ASC 830-10, "Foreign Currency Matters". All transactions gains and losses of the re-measurement of monetary balance sheets items are reflected in the consolidated statements of comprehensive loss as financial income or expenses, as appropriate.
Principles of consolidation
		c.	Principles of consolidation:
	The consolidated financial statements include the accounts of the Company and its Subsidiary. Intercompany transactions and balances have been eliminated upon consolidation.
Cash equivalents		d.	Cash equivalents:
	Cash equivalents include short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less from time of deposit.
Prepaid expenses
		e.	Prepaid expenses:
	All prepaid expenses are composed of clinical trials drug-kits which expense based on a percentage of completion method of the related clinical trials.
Investment in Parent company
		f.	Investment in Parent company:
	In accordance with ASC320, the accounting for the Company's investment in the equity securities depend on the remaining period of the tradability restriction in its respective market of the shares (as described in Note 1b).
	Shares that are restricted for less than one year re-measured to reflect fair value at each cutoff date. These securities are classified as available-for-sale securities carried at fair value, with unrealized gains and losses reported as a separate component of stockholders' equity under accumulated other comprehensive income in the consolidated balance sheets. Realized gains and losses on sales of available-for-sale securities are included as financials income, net in the consolidated statements of comprehensive loss. As of December 31, 2014, there are no restrictions on selling such shares.
	The Company recognizes an impairment charge when a decline in the fair value of its investments in securities is below the cost basis of such securities is judged to be other than temporary. Factors considered in making such a determination include the duration and severity of the impairment, the reason for the decline in value, the potential recovery period and the Company's intent to sell, including whether it is more likely than not that the Company will be required to sell the investment before recovery of cost basis. For securities that are deemed other-than-temporarily impaired, the amount of impairment recognized as part of financial income, net, net in the statement of comprehensive loss and is limited to the amount related to credit losses, while impairment related to other factors recognized in other comprehensive loss. As of December 2014 and 2013 no impairment was recognized.
Property and equipment, net	g.	Property and equipment, net:
			Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets at the following annual rates:
				%
		Computer equipment			33
Impairment of long-lived assets
		h.	Impairment of long-lived assets:
	The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360, "Property, Plant and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. As of December 31, 2014 and 2013, no impairment losses have been identified.
Research and development expenses
		i.	Research and development expenses:
	All research and development costs are charge to expense as incurred.
Accounting for stock-based compensation
		j.	Accounting for stock-based compensation:
	The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation" ("ASC 718"). ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company's consolidated statements of comprehensive loss.
	The Company recognizes compensation expenses for the value of its awards granted based on the accelerated recognition method over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	The Company estimates the fair value of stock options granted using the binomial option pricing-model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the early exercise multiply. Expected volatility was calculated based upon historical volatilities of similar entities in the related sector index. The early exercise multiply is representing the value of the underlying stock as a multiple of the exercise price of the option which, if achieved, results in exercise of the option. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
	The Company applies ASC 505-50, "Equity-Based Payments to Non-Employees" with respect to options and warrants issued to non-employees.
		k.	Basic and diluted net loss per share:
			Basic net loss per share is computed based on the weighted average number of shares of Common Stock, par value $0.001 per share (the "Common Stock") outstanding during each period. Diluted net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each period, plus dilutive potential Common Stock considered outstanding during the period, in accordance with ASC topic 260, "Earnings Per Share" ("ASC 260").
	The total weighted average number of shares related to the outstanding warrants and options excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,453,638 and 1,437,315 for the years ended December 31, 2014 and 2013, respectively.
Basic and diluted net loss per share	k.	Basic and diluted net loss per share:
	Basic net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each period. Diluted net loss per share is computed based on the weighted average number of shares of Common Stock outstanding during each period, plus dilutive potential Common Stock considered outstanding during the period, in accordance with ASC topic 260, "Earnings Per Share" ("ASC 260").
	The total weighted average number of shares related to the outstanding warrants and options excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,453,638 and 1,437,315 for the years ended December 31, 2014 and 2013, respectively.
Income taxes
		l.	Income taxes:
	The Company and its Subsidiary account for income taxes and uncertain tax positions in accordance with ASC 740, "Income Taxes" ("ASC 740"). ASC 740 prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company and its subsidiary provide a full valuation allowance, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized.
	The Company implements a two-step approach to recognize and to measure uncertain tax positions in accordance with ASC 740. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2014 and 2013, no liability for unrecognized tax benefits was recorded as a result of the implementation of ASC 740.
Concentrations of credit risk
		m.	Concentrations of credit risk:
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, investment in Parent company and prepaid expenses.
	Cash and cash equivalents are deposited with a major bank in Israel. The Company's management believes that the financial institution that holds the Company's investments is an institution with high credit standing, and accordingly, minimal credit risk exists with respect to these investments.
Fair value of financial instruments
		n.	Fair value of financial instruments:
	The carrying amounts of the Company's financial instruments, including cash and cash equivalents, investment in Parent company, prepaid expenses, accounts receivable, other accounts payable and accrued expenses, approximate fair value because of their generally short-term maturities.
	The Company adopted ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"). ASC 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to release a liability in an orderly transaction between market participants.
	As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
		Level 1 -	Observable input that reflects quoted prices (unadjusted) for identical assets or liabilities in active markets.
		Level 2 -	Include other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and credit ratings.
		Level 3 -	Unobservable inputs which are supported by little or no market activity.
			The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
Impact of recently issued Accounting Standards
		o.	Impact of recently issued Accounting Standards:
	In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. Although the Company has elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the Jumpstart Our Business Act of 2012, since early adoption is permitted the Company chose to early adopt the update effective June 30, 2014 consolidated financial statement.
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity s Ability to Continue as a Going Concern, which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Significant Accounting Policies [Abstract]
Schedule of Property and equipment, net			%
		Computer equipment	33

Derivative_Related_to_Service_1

Derivative Related to Service Agreement (Tables)	12 Months Ended
	Dec. 31, 2014
Derivative Related to Service Agreement [Abstract]
Schedule of derivative fair value assumptions				31-Dec
				2014			2013
		Risk-free interest rate (1)			0.54	%		0.78	%
		Expected volatility (2)			57.51	%		58.41	%
		Expected life (in years) (3)			1.92			2.92
		Expected dividend yield (4)			0			0
		-1	Risk-free interest rate - based on the yields from U.S. treasury bonds with different periods to maturity (according to different projection periods).
		-2	Expected volatility - was calculated based on actual historical stock price movements of the Parent Company over a term that is equivalent to the expected term of the option.
		-3	Expected life - the expected life of the conversion feature was based on the term of the derivative.
		-4	Expected dividend yield - was based on the fact that the Company has not paid dividends to its stockholders in the past and does not expect to pay dividends to stockholders in the foreseeable future.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Measurements [Abstract]
Summary of financial assets and liabilities measured at fair value on recurring basis				31-Dec-14
				Fair value measurements
		Description		Fair Value			Level 1(1)		Level 2(2)		Level 3(3)
		Investment in Parent company		$	794		$	794	$	-	$	-
		Derivative related to Service Agreement			*	)		-		-		*	)
		Total Financial Assets, net		$	794		$	794	$	-	$	-
	*) Represent amount lower than $1
				31-Dec-13
				Fair value measurements
		Description		Fair Value			Level 1(1)		Level 2(2)		Level 3(3)
		Investment in Parent company		$	1,175		$	514	$	661	$	-
		Derivative related to Service Agreement			(7	)		-		-		(7	)
		Total Financial Assets, net		$	1,168		$	514	$	661	$	(7	)
		-1	Represents the portion of the Parent company's shares that has no trading restrictions.
		-2	Represents the portion of the Parent company's shares that has trading restrictions.
		-3	Fair value measurements using significant unobservable inputs (Level 3).
Summary of changes in level 3 instruments measured on recurring basis		Balance at January 1, 2013		$	470
		Change in fair value of derivatives			(463	)
		Balance at December 31, 2013			7
		Change in fair value of derivatives			(7	)
		Balance at December 31, 2014			*	)
	*) Represent amount lower than $1

Share_Capital_Tables

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2014
Share Capital [Abstract]
Schedule of estimated fair values of stock options granted
			Year ended
			December 31,
		Description	2014			2013
		Risk-free interest rate		-			1.72%-2.5%
		Expected volatility		-			68.5%-71.6%
		Dividend yield		-			0
		Contractual life		-			10
		Early Exercise Multiple (Suboptimal Factor)		-			3
		Fair value of options granted during the period		-		$	0.54-0.6
Schedule of stock options activity
			Shares Subject to Options Outstanding
		Description	Number of			Weighted		Weighted-		Aggregate
			Shares			Average		Average
						Exercise		Remaining		Intrinsic
						Price		Contractual
								Term (in years)		Value(1) (in thousands)
		Outstanding at beginning of year		326,324			6.25		9.15	$	-
		Forfeited/cancelled		(208,824	)		5.29		-		-
		Outstanding at the end of year		117,500			7.96		7.8	$	-
		Exercisable at the end of the year		88,125			8.39		7.6	$	-
		Vested and expected to be vested		117,500			7.96		7.8	$	-

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of loss before taxes
			Year ended
			December 31,
			2014			2013
		Domestic	$	367		$	869
		Foreign (Israel)		828			1,968
			$	1,195		$	2,837
Schedule of deferred tax assets			December 31,
			2014			2013
		Operating loss carryforward	$	1,268		$	952
		Research and development expenses		205			229
		Investment in Parent company		282			130
		Deferred tax assets before valuation allowance		1,755			1,311
		Valuation allowance		(1,755	)		(1,311	)
		Net deferred tax asset	$	-		$	-

Finance_Expenses_Income_Net_Ta

Finance Expenses (Income), Net (Tables)	12 Months Ended
	Dec. 31, 2014
Finance Expenses (Income), Net [Abstract]
Schedule of finance expenses (income) net			Year ended
			December 31,
			2014			2013
		Bank fees	$	4		$	4
		Interest expenses		52			17
		Revaluation of derivative related to service agreement		(7	)		(463	)
		Loss from sale of Parent company shares		-			26
		Foreign currency translation adjustments		*	)		(17	)
		Finance expenses (income), net	$	49		$	(433	)

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Schedule of transactions with related parties			Year ended
			December 31,
			2014			2013
		Research and development expenses (1)	$	701		$	1,530
		General and administrative expenses (2)	$	115		$	152
		Finance expenses (income), net (1)	$	45		$	(446	)
Schedule of balances with related parties			December 31,
			2014			2013
		Parent company (1)	$	(2,457	)	$	(1,487	)
		Investment in Parent company (3)	$	794		$	1,175
		Other account payables and accrued expenses (1)	$	(175	)	$	(175	)
		Derivative related to service agreement (1)	$	*	)	$	(7	)

General_Details

General (Details) (USD $)	12 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Nov. 21, 2011	Dec. 31, 2013	Jun. 17, 2013	Nov. 21, 2012
General [Textual]
Common Stock, par value	$0.00		$0.00
Accrued for milestones payment	$175
License agreement terms	License agreement between the Company and NIH remains in effect, a nonrefundable minimum annual royalty fee and potential future royalties of 4.0% to 5.5% on net sales.
Deferred payments	2,457		1,487
Private Placement [Member]
General [Textual]
Total consideration received for sale of stock	3,330
Common Stock converted to additional payment	646,776
Maximum [Member]
General [Textual]
Payment for milestone	500
Minimum [Member]
General [Textual]
Payment for milestone	25
Eye-Fite Ltd [Member]
General [Textual]
Shares issued for acquired outstanding shares		8,000,000
Shares issued, price per share		$5.15
Accrual clinical trials cost			75
Percentage of sublicensing revenues			20.00%
Can-Fite [Member]
General [Textual]
Common stock shares issued	466,139	480,022
Common stock value issued	2,400
Ordinary shares received	714,922
Percentage of issued and outstanding share capital on Closing Date	7.00%
Total consideration received for sale of stock	2,471			511
Ordinary shares held	446,827			268,095
Percentage of issued and outstanding share capital	2.05%				12.50%
Warrants exercisable period	5 years
Exercise price of the warrants	$7.74
Recapitalization transaction description	For each four shares of the Company's Common Stock purchased in the Financing, nine warrants valid for a period of five years from the closing of the Financing to acquire two shares of the Company for an exercise price of $7.74.
Percentage of expenses	15.00%
Future additional payments percentage	2.50%
Common Stock converted to additional payment	480,022			268,095
Interest rate on deferred payments	3.00%
Deferred payments	2,457
Gross proceeds	500
Shares issued	97,112
Stock transaction percentage	82.00%
Ophthalix [Member]
General [Textual]
Equity method investment additional amount	$500

Significant_Accounting_Policie3

Significant Accounting Policies (Details)	Dec. 31, 2014
Property, Plant and Equipment, Net [Abstract]
Computer equipment	33.00%

Significant_Accounting_Policie4

Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Significant Accounting Policies (Textual)
Anti-dilutive share	1,453,638	1,437,315
Common Stock, par value	$0.00	$0.00

Investment_in_Parent_Company_D

Investment in Parent Company (Details) (USD $)	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 17, 2013	Dec. 31, 2014		Dec. 31, 2013
Investment [Line Items]
Net loss		$1,195		2,837
Risk-free interest rate (1)		0.54%	[1]	0.78%	[1]
Dividend yields		0.00%	[2]	0.00%	[2]
Weighted-average contractual life		1 year 11 months 1 day	[3]	2 years 11 months 1 day	[3]
Investment in Parent company (Note 3)		794		1,175
Unrealized gain from investment in Parent company		-381		483
Can-Fite [Member]
Investment [Line Items]
Common shares sold for considertion	268,095	480,022
Total consideration received for sale of stock	511	2,471
Net loss	$26
Dividend yields				0.00%
Volatility factors				77.40%
Outstanding ordinary shares	268,095	446,827
Can-Fite [Member] | Maximum [Member]
Investment [Line Items]
Risk-free interest rate (1)				0.93%
Weighted-average contractual life				7 months 21 days
Can-Fite [Member] | Minimum [Member]
Investment [Line Items]
Risk-free interest rate (1)				0.89%
Weighted-average contractual life				1 month 21 days
[1]	(1) Risk-free interest rate - based on the yields from U.S. treasury bonds with different periods to maturity (according to different projection periods).
[2]	(4) Expected dividend yield - was based on the fact that the Company has not paid dividends to its stockholders in the past and does not expect to pay dividends to stockholders in the foreseeable future.
[3]	(3) Expected life - the expected life of the conversion feature was based on the term of the derivative.

Derivative_Related_to_Service_2

Derivative Related to Service Agreement (Details)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Derivative Related to Service Agreement [Abstract]
Risk-free interest rate (1)	0.54%	[1]	0.78%	[1]
Expected volatility (2)	57.51%	[2]	58.41%	[2]
Expected life (in years) (3)	1 year 11 months 1 day	[3]	2 years 11 months 1 day	[3]
Expected dividend yield (4)	0.00%	[4]	0.00%	[4]
[1]	(1) Risk-free interest rate - based on the yields from U.S. treasury bonds with different periods to maturity (according to different projection periods).
[2]	(2) Expected volatility - was calculated based on actual historical stock price movements of the Parent Company over a term that is equivalent to the expected term of the option.
[3]	(3) Expected life - the expected life of the conversion feature was based on the term of the derivative.
[4]	(4) Expected dividend yield - was based on the fact that the Company has not paid dividends to its stockholders in the past and does not expect to pay dividends to stockholders in the foreseeable future.

Derivative_Related_to_Service_3

Derivative Related to Service Agreement (Details Textual) (USD $)	12 Months Ended		1 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Nov. 21, 2011	Dec. 31, 2011
Subsidiary or Equity Method Investee [Line Items]
Gain on derivative	$438,000
Issuance expenses	49,000	-433,000
Fair value of derivative	0	7,000
Service Agreement [Member]
Subsidiary or Equity Method Investee [Line Items]
Common shares sold for considertion			480,022
Aggregate price for shares			2,500,000
Exercise price of share			$5.15
Issuance expenses				$50,000
Can-Fite's [Member] | Service Agreement [Member]
Subsidiary or Equity Method Investee [Line Items]
Percentage of expenses			15.00%
Future additional payments percentage			2.50%

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Recurring [Member], USD $)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in Parent Company	$794		$1,175
Derivative related to Service Agreement		[1]	-7
Total Financial Assets, net	794		1,168
Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in Parent Company	794		514	[2]
Derivative related to Service Agreement				[2]
Total Financial Assets, net	794		514	[2]
Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in Parent Company			661	[3]
Derivative related to Service Agreement				[3]
Total Financial Assets, net			661	[3]
Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in Parent Company				[4]
Derivative related to Service Agreement		[1]	-7	[4]
Total Financial Assets, net			($7)	[4]
[1]	Represent amount lower than $1
[2]	Represents the portion of the Parent company's shares that has no trading restrictions.
[3]	Represents the portion of the Parent company's shares that has trading restrictions.
[4]	Fair value measurements using significant unobservable inputs (Level 3).

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Fair Value Measurements [Abstract]
Beginning Balance	$7		$470
Change in fair value of derivatives	-7		-463
Ending Balance		[1]	$7
[1]	Represent amount lower than $1

Share_Capital_Details

Share Capital (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate minimum		1.72%
Risk-free interest rate maximum		2.50%
Expected volatility maximum		71.60%
Expected volatility minimum		68.50%
Dividend yield		0.00%
Contractual life		10 years
Early Exercise Multiple (Suboptimal Factor)		$3
Fair value of options granted during the period
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of options granted during the period		$0.60
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of options granted during the period		$0.54

Share_Capital_Details_1

Share Capital (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Shares, Outstanding			326,324
Number of Shares, Outstanding	117,500		326,324
Number of Shares, Exercisable	74,525
Number of Shares, Vested and expected to be vested	117,500
Weighted Average Exercise Price, Outstanding			$6.25
Weighted Average Exercise Price, Outstanding	$7.96		$6.25
Weighted Average Exercise Price, Exercisable	$8.45
Weighted Average Exercise Price, Vested and expected to be vested	$7.96
Aggregate Intrinsic Value, Outstanding
Aggregate Intrinsic Value, Outstanding
Aggregate Intrinsic Value, Exercisable
Aggregate Intrinsic Value, Vested and expected to be vested
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Shares, Outstanding	326,324
Number of shares, Forfeited/cancelled	-208,824
Number of Shares, Outstanding	117,500
Number of Shares, Exercisable	88,125
Number of Shares, Vested and expected to be vested	117,500
Weighted Average Exercise Price, Outstanding	$6.25
Weighted Average Exercise Price, Forfeited/cancelled	$5.29
Weighted Average Exercise Price, Outstanding	$7.96
Weighted Average Exercise Price, Exercisable	$8.39
Weighted Average Exercise Price, Vested and expected to be vested	$7.96
Weighted Average Remaining Contractual Term, Outstanding (in years)	9 years 1 month 24 days
Weighted Average Remaining Contractual Term, Outstanding (in years)	7 years 9 months 18 days
Weighted Average Remaining Contractual Term, Exercisable (in years)	7 years 7 months 6 days
Weighted Average Remaining Contractual Term, Vested and expected to be vested (in years)	7 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding		[1]
Aggregate Intrinsic Value, Forfeited/cancelled		[1]
Aggregate Intrinsic Value, Outstanding		[1]
Aggregate Intrinsic Value, Exercisable		[1]
Aggregate Intrinsic Value, Vested and expected to be vested		[1]
[1]	The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the closing price of the shares of the Company's Common Stock of $0.96 as of December 31, 2014.

Share_Capital_Details_Textual

Share Capital (Details Textual) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Apr. 22, 2013

Feb. 28, 2013

Jan. 02, 2012

Dec. 12, 2012

Jun. 02, 2014

Jun. 17, 2013

9-May-13

Jul. 18, 2013

Jan. 31, 2012

Nov. 12, 2012

Share Capital Textual [Abstract]

Warrants expiration period

8 months 12 days

Dividend yield

0.00%

Contractual life

10 years

Exercise price

$3

Reserved for issuance, common stock par value

$0.00

$0.00

Stock based compensation

$25

$598

Stock option plan [Member]

Share Capital Textual [Abstract]

Stock option plan term description

Each Stock option granted shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will be granted with a term in excess of 10 years.

Reserved for issuance, common stock

1,088,888

Reserved for issuance, common stock par value

$0.00

Common stock available for future grant

971,388

Expiration, Granted

10 years

Compensation owed to the CEO under the Employment Agreement

He will devote approximately 50% of his time to each position and the Company will pay one-half of the compensation owed to the CEO under the Employment Agreement.

Options issued to purchase common stock

104,412

Options exercise price

$5.29

Reversed compensation related to unvested option

85

Former CEO [Member] | Stock option plan [Member]

Share Capital Textual [Abstract]

Employment agreement description

The Board of Directors of the Company approved the appointment of a Chief Executive Officer ("Former CEO") of the Company effective January 1, 2013. The Board of Directors also approved an employment agreement of the Former CEO, which became effective on January 1, 2013. The agreement was terminated on February 25, 2013.

Options issued to purchase common stock

8,701

Options exercise price

$5.29

CEO [Member] | Stock option plan [Member]

Share Capital Textual [Abstract]

Vested period description

All of the vested options were exercisable 90 days from the effective date and none were exercised.

Expiration, Granted

10 years

Employment agreement description

Employment agreement was terminated effective July 28, 2014.

Options issued to purchase common stock

104,412

Options exercise price

$5.29

Board of Directors [Member] | Stock option plan [Member]

Share Capital Textual [Abstract]

Options issued to purchase common stock

469,855

52,222

Options exercise price

$5.29

$6.64

Stock Compensation unrecognized, Cancellation value

211

Options vest description

1/12th vested on September 30, 2013 and 1/12th of the total options vest on the last day of each 11 quarters thereafter so long as he remains a director, until fully vested.

Chief Financial Officer [Member] | Stock option plan [Member]

Share Capital Textual [Abstract]

Options issued to purchase common stock

13,055

Options exercise price

$9

Granted Options expiring date

29-May-23

Options vest immediately

29,375

Option vest over the period

29,375

Stock based compensation

62

Share based compensation modification

38

Stock Compensation unrecognized, Cancellation value

211

Common Stock [Member]

Share Capital Textual [Abstract]

Reverse stock split

stock split of one share for each four and one-half shares outstanding (1:4.5)

Exercise price

$0.96

Common Stock [Member] | Stock option plan [Member]

Share Capital Textual [Abstract]

Number of shares, Granted

52,222

Exercise price, Granted

$9

Vested period description

The options shall be vested in a period of 36 months so long as he remains a director until fully vested.

Expiration, Granted

10 years

Warrant [Member]

Share Capital Textual [Abstract]

Exercise price of the warrants

$7.74

Warrants expiration period

5 years

Warrants issued to purchase common stock

532,870

Common shares sold for considertion

118,415

Fair value of warrants

329

Stock issuance expenses paid in cash

304

Financial expenses

$25

Risk-free interest rates

0.92%

Dividend yield

0.00%

Volatility rate

76.23%

Contractual life

3 years 8 months 19 days

Exercise price

$5.15

Expiration, Granted

5 years

Warrant [Member] | Investors [Member]

Share Capital Textual [Abstract]

Exercise price of the warrants

$7.74

Warrants expiration period

5 years

Warrants issued to purchase common stock

1,455,228

Common shares sold for considertion

323,384

Expiration, Granted

5 years

Warrant [Member] | Can Fite [Member]

Share Capital Textual [Abstract]

Exercise price of the warrants

$7.74

Warrants expiration period

5 years

Warrants issued to purchase common stock

1,267,315

Common shares sold for considertion

281,625

Expiration, Granted

5 years

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Domestic	$367	$869
Foreign (Israel)	828	1,968
Current Income Tax Expense (Benefit)	$1,195	$2,837

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]
Operating loss carryforward	$1,268	$952
Research and development expenses	205	229
Investment in Parent company	282	130
Deferred tax assets before valuation allowance	1,755	1,311
Valuation allowance	-1,755	-1,311
Net deferred tax asset

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Net operating loss carryforwards for federal income tax	$1,503
Tax credit carryforward description	2018 to 2034
Corporate tax rate	40.00%
Progressive corporate tax rate	35.00%
Israel [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign accumulated losses	$2,523
Foreign corporate tax rate	26.50%	25.00%

Finance_Expenses_Income_Net_De

Finance Expenses (Income), Net (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Finance Expenses (Income), Net [Abstract]
Bank fees	$4		$4
Interest expenses	52		17
Revaluation of derivative related to service agreement	-7		-463
Loss from sale of Parent company shares			26
Foreign currency translation adjustments		[1]	-17
Finance expenses (income), net	$49		($433)
[1]	Represent amount lower than $1

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Transactions with related parties:
General and administrative expenses (2)	($425)		($1,511)
Related Parties [Member]
Transactions with related parties:
Research and development expenses (1)	701	[1]	1,530	[1]
General and administrative expenses (2)	115	[2]	152	[2]
Finance expenses (income), net (1)	$45	[1]	($446)	[1]
[1]	Related to Service Agreement. (See Notes 1.b.2 and 1c).
[2]	Related to Service Agreement. (See Notes 1.b.2 and 1c) and to the CEO employment agreement.

Related_Party_Transactions_Det1

Related Party Transactions (Details 1) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Balances with Related Parties:
Parent company (1)	$2,457		$1,487
Investment in Parent company (3)	794		1,175
Other account payables and accrued expenses (1)	-175	[1]	-175	[1]
Derivative related to service agreement (1)		[2]	$7
[1]	Related to Service Agreement. (See Notes 1.b.2 and 1c).
[2]	Represent amount lower than $1